Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2014

View Archived Issues

Cleave Biosciences presents new lead compound CB-5083 for tumors

Phase II evaluation of an AT2 receptor antagonist for postherpetic neuralgia

TK-001, TK-002 and TK-003 to be outlicensed after phase Ib

LUTE and VERSE study data show efficacy for lebrikizumab in uncontrolled asthma

A first-in-class melanocortin MC4 receptor agonist for the treatment of sexual dysfunction

NDA for lubiprostone liquid formulation will not be filed this year

Five Prime Therapeutics and BMS sign collaboration for immuno-oncology therapies

Votrient receives an additional indication approval in Japan

Merck & Co. designs new agents for diabetes and other disorders

Amgen reports topline results from the phase III TESLA trial

Novel, selective 5-HT5A receptor antagonist as a potential treatment for schizophrenia

Allermist approved in Japan for pediatric allergic rhinitis

Treventis discloses novel agents for Alzheimer's disease

Boehringer Ingelheim synthesizes novel neutrophil elastase inhibitors

NVS-CRF38, a new CRF1 receptor antagonist, described by Novartis

Theracos reports data from phase II study of THR-1442 in type 2 diabetes

Researchers at Alios BioPharma present novel antiviral agents

NeoStem reports on fourth data safety monitoring board review of PreSERVE AMI trial

uniQure and Chiesi Farmaceutici report 6-year follow-up data for Glybera

Amorfix and Trellis Bioscience to collaborate on anti-CD38 cancer treatment

Cardium Therapeutics changes name to Taxus Cardium Pharmaceuticals

MD Anderson and MedImmune collaborate on cancer immunotherapy

ATL-1102 studied in phase I stem cell mobilization study

Resolve Therapeutics initiates clinical development of RSLV-132 for SLE

FDA approves Hemangeol for infantile hemangioma

FDA clears Summit to begin phase II study of SMT-19969 in C. difficile infection

SillaJen completes acquisition of Jennerex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...